NasdaqFinancialsLife & Health InsuranceS&P SmallCap 600
$36.75
+2.03 (+5.85%)
Close of Nov 06, 2026 · end-of-day data
TRUP 8-K filings in 2026
Every material Form 8-K Trupanion filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Trupanion reported third-quarter 2026 results for the period ended September 30, 2026. Total revenue rose 11% to $405.6 million, net income was $9.3 million, or $0.21 per diluted share, compared with $5.9 million, or $0.13 per diluted share, a year earlier. The company also repurchased about $25.0 million of its stock in the quarter, leaving about $75.0 million available under its $100.0 million buyback program.
Total revenue was $405.6 million, up 11% from $366.9 million in Q3 2025.
Net income was $9.3 million, or $0.21 per diluted share, versus $5.9 million, or $0.13 per diluted share, in Q3 2025.
Adjusted EBITDA was $20.8 million, compared with $19.6 million in Q3 2025.
Operating cash flow was $30.7 million and free cash flow was $28.5 million in Q3 2026; about $25.0 million of stock was repurchased in the quarter.
Trupanion reported second-quarter 2026 results with total revenue of $392.9 million, up 11% from a year earlier, but net income fell to $6.8 million, or $0.16 per diluted share, from $9.4 million, or $0.22, in the second quarter of 2025. The Board also approved a share repurchase program of up to $100.0 million with no expiration date, which gives the company authority to buy back stock but does not commit it to a specific amount.
Total revenue was $392.9 million, up 11% from the second quarter of 2025; subscription business revenue was $276.7 million, up 14%.
Net income was $6.8 million, or $0.16 per diluted share, versus $9.4 million, or $0.22, in the second quarter of 2025.
The Board approved a repurchase program of up to $100.0 million of common stock in June 2026, with no expiration date.
The New York Department of Financial Services approved a $44 million extraordinary dividend from American Pet Insurance Company to Trupanion in July 2026.
Trupanion reported first quarter 2026 results on April 30, 2026. Total revenue rose 12% to $384.0 million and the company swung to net income of $4.9 million, or $0.11 per diluted share, from a net loss of $1.5 million a year earlier, while adjusted EBITDA rose to $17.4 million from $12.2 million. Total enrolled pets fell 2% year over year, though subscription pets rose 5%.
Total revenue $384.0 million, up 12% from the first quarter of 2025
Net income $4.9 million, or $0.11 per diluted share, versus a net loss of $1.5 million, or $(0.03) per share, a year earlier
Adjusted EBITDA $17.4 million, versus $12.2 million in the first quarter of 2025
Operating cash flow $14.6 million and free cash flow $13.7 million, versus $16.0 million and $14.0 million a year earlier; total enrolled pets were 1,637,665, down 2%
Director Max Brodén told Trupanion on April 22, 2026 that he will not stand for re-election at the June 10, 2026 annual meeting, citing personal reasons. He will remain on the board until that meeting, and the filing says Aflac's strategic partnership with Trupanion is unaffected. The same day, Trupanion filed its 2025 Annual Report, which includes a shareholder letter, but the 8-K does not report any financial results.
Director Max Brodén will not stand for re-election; notice given April 22, 2026
Brodén's departure is for personal reasons, not a disagreement with Trupanion or the board
Annual Stockholders' Meeting set for 9 am Pacific Time on June 10, 2026
2025 Annual Report with shareholder letter filed April 27, 2026
Trupanion reported fourth-quarter and full-year 2025 results on February 12, 2026. Fourth-quarter total revenue rose 12% to $376.9 million, and net income was $5.6 million, or $0.13 per diluted share, compared with $1.7 million, or $0.04, a year earlier. Full-year 2025 net income was $19.4 million, or $0.45 per share, versus a net loss of $9.6 million in 2024, though that result includes a $7.8 million realized gain from exchanging a preferred stock investment for intellectual property.
Q4 2025 adjusted EBITDA was $21.8 million, compared with $19.4 million in Q4 2024.
Full-year 2025 total revenue was $1,439.3 million, up 12%; subscription revenue was $989.3 million, up 16%.
Total enrolled pets fell 2% to 1,647,565 at December 31, 2025, while subscription enrolled pets rose 5% to 1,096,173.
Q4 2025 operating cash flow was $29.3 million and free cash flow was $25.3 million; the company held $370.7 million in cash and short-term investments at year-end.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Trupanion filing is on SEC EDGAR ↗. 8-K briefs of other companies →